Thus, identifying distinct FAP subsets based on their sensitivity to metformin could lead to the identification of a novel druggable cell-based target for reducing fibrosis and IMAT deposition in T2DM patients. This evidence concerns the gene FAP and type 2 diabetes mellitus.